Clonidine and the anti-parkinsonian response to L-DOPA or piribedil.
D000368:Aged; D002230:Carbidopa / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003000:Clonidine / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010879:Piperazines / Q000037:antagonists & inhibitors*; D010891:Piribedil / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D010919:Placebos
D010879:Piperazines; D010919:Placebos; D007980:Levodopa; D010891:Piribedil; D003000:Clonidine; D002230:Carbidopa